| Core Benefits of Stabilitech’s Technology: |
|
| Removes the need for cold chain / refrigerated storage |
 |
| Removes risk of freeze damage |
|
| Protects against temperature fluctuations (e.g. -20°C to +37°C) |
|
| Enables long-term storage of thermally sensitive vaccines and biopharmaceuticals |
|
| Prevents inadvertent administration of heat-inactivated vaccine |
|
| Facilitates stockpiling eg for pandemic influenza and biodefence vaccines |
|
| Provides competitive advantage through product differentiation and enabling patent extension |
|
| |
|
| Applicability: |
|
| Viruses: live, enveloped, non-enveloped & inactivated |
|
| Vaccines: viral, sub-unit & adjuvanted |
|
| Biopharmaceuticals: peptides, proteins eg antibodies, growth factors, enzymes etc |
|
| |
|
| Safe, robust, simple: |
|
| Excipients have all previously been used in clinical settings |
|
| Can be easily be integrated into existing cGMP manufacturing processes |
|
| Uses standard manufacturing equipment |
|
| Low Cost of Goods (COGS) |
|
